Paper · 37445352
Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors.
Michalak N and 1 other. J Clin Med, 2023. Cited by 19 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors. Papers, record 37445352. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37445352
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 503/1-002-01/503-11-001-19-00 | Medical University of Łódź, Poland | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References124
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22,614,008 | Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through α7nAChR-mediated MUC4 upregulation. | Oncogene | 2013 | https://conductscience.org/library/papers/22614008 | PubMed |
| 2 | 16,091,975 | The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. | J Cancer Res Clin Oncol | 2005 | https://conductscience.org/library/papers/16091975 | PubMed |
| 3 | 34,855,203 | Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: A prospective cohort study. | Int J Cancer | 2022 | https://conductscience.org/library/papers/34855203 | PubMed |
| 4 | 29,567,829 | The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. | Cancer Discov | 2018 | https://conductscience.org/library/papers/29567829 | PubMed |
| 5 | 33,934,530 | Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES). | Cancer Med | 2021 | https://conductscience.org/library/papers/33934530 | PubMed |
| 6 | 10,640,982 | Orthotopic human lung carcinoma xenografts in BALB/c mice immunosuppressed with anti-CD4 monoclonal antibodies and chronic alcohol consumption. | Cancer | 2000 | https://conductscience.org/library/papers/10640982 | PubMed |
| 7 | 31,398,337 | Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. | Cell | 2019 | https://conductscience.org/library/papers/31398337 | PubMed |
| 8 | 30,383,737 | Surveillance for Cancers Associated with Tobacco Use - United States, 2010-2014. | MMWR Surveill Summ | 2018 | https://conductscience.org/library/papers/30383737 | PubMed |
| 9 | 23,534,737 | Chronic hepatitis B virus infection and risk of pancreatic cancer: a meta-analysis. | Asian Pac J Cancer Prev | 2013 | https://conductscience.org/library/papers/23534737 | PubMed |
| 10 | 28,915,646 | Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. | Oncotarget | 2017 | https://conductscience.org/library/papers/28915646 | PubMed |
1 to 10 of 124
See all 124 referencesCited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,509,736 | High-Dimensional Immunophenotyping of Plasma-Derived Small Extracellular Vesicles in Pancreatic Cancer: An Exploratory Proof-of-Principle Study. | Biomolecules | 2026 | https://conductscience.org/library/papers/42509736 | PubMed |
| 42,164,697 | Circulating inflammatory indices refine prognostic stratification and complication risk in pancreatic cancer following radical surgery. | Gland Surg | 2026 | https://conductscience.org/library/papers/42164697 | PubMed |
| 41,904,584 | Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment. | Mol Cancer | 2026 | https://conductscience.org/library/papers/41904584 | PubMed |
| 41,852,430 | Obesity reprograms the normal pancreas and pancreatic cancer microbiome in mice and humans. | Front Microbiomes | 2025 | https://conductscience.org/library/papers/41852430 | PubMed |
| 41,847,441 | Bibliometric analysis of the trends in research on the link between gut microbiota and pancreatic cancer. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/41847441 | PubMed |
| 41,692,706 | Toward Timely Diagnosis of Pancreatic Cancer: Revolutionizing Early Detection Through Genomics, Artificial Intelligence, and Noninvasive Biomarkers. | J Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41692706 | PubMed |
| 41,142,718 | Integrated Multiomics Validation of Key MUC Gene Expression for the Signature Biomarker in the Pakistani Cohort. | Biomed Res Int | 2025 | https://conductscience.org/library/papers/41142718 | PubMed |
| 40,668,426 | The role of visfatin and omentin-1 gene polymorphism in pancreatic ductal adenocarcinoma (PDAC). | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/40668426 | PubMed |
| 40,210,335 | The exposome as a target for primary prevention and a tool for early detection of pancreatic cancer. | Best Pract Res Clin Gastroenterol | 2025 | https://conductscience.org/library/papers/40210335 | PubMed |
| 40,001,578 | The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications. | Biomolecules | 2025 | https://conductscience.org/library/papers/40001578 | PubMed |
1 to 10 of 17
See all 17 cited byGenes38
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ADH1B | 125 | PubTator's text mining | https://conductscience.org/library/genes/125 | NCBI Gene |
| ADH1C | 126 | PubTator's text mining | https://conductscience.org/library/genes/126 | NCBI Gene |
| ADIPOQ | 9,370 | PubTator's text mining | https://conductscience.org/library/genes/9370 | NCBI Gene |
| AHR | 196 | PubTator's text mining | https://conductscience.org/library/genes/196 | NCBI Gene |
| AKR1A1 | 10,327 | PubTator's text mining | https://conductscience.org/library/genes/10327 | NCBI Gene |
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| ALDH2 | 217 | PubTator's text mining | https://conductscience.org/library/genes/217 | NCBI Gene |
| APLN | 8,862 | PubTator's text mining | https://conductscience.org/library/genes/8862 | NCBI Gene |
| CCK | 885 | PubTator's text mining | https://conductscience.org/library/genes/885 | NCBI Gene |
| CCL2 | 6,347 | PubTator's text mining | https://conductscience.org/library/genes/6347 | NCBI Gene |
1 to 10 of 38
See all 38 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37445352
GET https://conductscience.org/api/papers/v1/37445352/references?page=2